Remove 2027 Remove Packaging Remove Vaccines
article thumbnail

FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency

Pharmacy Times

Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.

FDA 97
article thumbnail

Merck concludes SpringWorks acquisition for $3.4bn

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. Give your business an edge with our leading industry insights.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi agrees to invest $25m in Adagene

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. As of December 2024, the company reported cash reserves of $85.2m.

article thumbnail

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

FDA 52
article thumbnail

Piramal Pharma announces $90m investment to expand US sites

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches. Give your business an edge with our leading industry insights.

article thumbnail

Subcutaneous Biologics Market Analysis: Current Trends and Future Outlook

Roots Analysis

It is important to note that, for the purpose of subcutaneous biologics market analysis, the biologics were segregated into antibodies , nucleotides, proteins and vaccines. The below figure presents the distribution of subcutaneous biologics based on initial approval year and type of biologic.

article thumbnail

Pre-Filled Syringes East Coast 2022

pharmaphorum

million in 2020 and with the rapid growth of the industry, is expected to grow at a CAGR of 8.95% up to 2027. Primary Packaging material designers. Secondary packagers. Device innovations, connected delivery and regulatory guidance for advanced parenteral systems. The global pre-filled syringes market was valued at $1139.6